Ovarian carcinoma (high-grade serous predominant) · line 2 · Mirvetuximab soravtansine (FRα-high platinum-resistant ovarian, MIRASOL)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-MIRVETUXIMAB-OVARIAN`

ID	`IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-OVARIAN`
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-MIRASOL-MOORE-2024` `SRC-NCCN-OVARIAN-2025`

Notes

ESCAT IA. UA-access: not registered as of 2026-04 — потребує клінічного дослідження або благодійного імпорту. Альтернатива з UA-доступом: REG-WEEKLY-PAC-BEV-OVARIAN або REG-PLD-BEV-OVARIAN.

Used By

Algorithms

ALGO-OVARIAN-2L - ALGO-OVARIAN-2L